CHINA JINMAO(00817) has accumulated a total signed sales amount of 98.255 billion yuan in the fiscal year 2024.
China Jinmao (00817) announced that in December 2024, the group obtained a contract sales amount of 1...
CHINA JINMAO (00817) announced that in December 2024, the group achieved a total signed sales amount of RMB 15.255 billion, with a signed sales building area of approximately 1.1982 million square meters. As of December 31, 2024, over the past 12 months, the group has accumulated a total signed sales amount of RMB 98.255 billion (including the transaction sales amounts of projects such as Changsha Meixi Lake International New Town, Nanjing Green Dragon Mountain International Ecological New Town, Ningbo Life Science City, Jiaxing Shanghai Window Smart Science City, Zhengzhou Erqi District Mazhai New Town, Wenzhou Aojiang International New Town, Jinhua Jinmao Future Science City, Huzhou Jinmao South Taihu Future Window, and Shanghai Hengmen City Operations project), as well as a cumulative signed sales building area of approximately 5.8184 million square meters.
Additionally, as of December 31, 2024, the group has obtained a total subscribed (unsigned) property sales amount of RMB 1.7 billion.
Related Articles
HK Stock Market Move | MINIEYE (02431) rose more than 10% during the day, the company launched the unmanned logistics brand "Xiaozhu unmanned vehicle" to achieve L4 level logistics autonomous driving.
HK Stock Market Move | TYK MEDICINES-B (02410) surged over 40%. The key registration phase II clinical results of Eliotinib were recently featured in the WCLC oral presentation.
HK Stock Market Move | BOAN BIOTECH (06955) rose more than 14%. The company currently has sufficient cash reserves and institutions are optimistic about its potential in the FIC innovation pipeline market.
HK Stock Market Move | MINIEYE (02431) rose more than 10% during the day, the company launched the unmanned logistics brand "Xiaozhu unmanned vehicle" to achieve L4 level logistics autonomous driving.
HK Stock Market Move | TYK MEDICINES-B (02410) surged over 40%. The key registration phase II clinical results of Eliotinib were recently featured in the WCLC oral presentation.
HK Stock Market Move | BOAN BIOTECH (06955) rose more than 14%. The company currently has sufficient cash reserves and institutions are optimistic about its potential in the FIC innovation pipeline market.
